Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic diseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study used a deep, global microarray-based method to characterize the diversity and temporal changes of the intestinal microbiota during infancy. The researchers aimed to define specific bacterial signatures associated with atopic eczema, since prior work had linked deviations in microbiota composition and diversity in infancy to both the development and recurrence of eczema. Faecal samples were profiled at two time points, 6 and 18 months of age, to track how the microbiota changed alongside eczema status.
Who was studied?
The study analyzed faecal microbiota from 34 infants, 15 with eczema and 19 healthy controls, selected from a prospective follow-up study based on availability of faecal samples. These infants were considered at-risk for atopic disease and had originally been randomized to receive either Lactobacillus rhamnosus GG or placebo. This gives the cohort a defined clinical and interventional context rather than being an anonymous public dataset.
What were the most important findings?
Children with eczema harboured a more diverse total microbiota than controls, as measured by the Simpson's reciprocal diversity index of the microarray profiles. Microbiota composition did not differ between groups at 6 months, but became significantly different by 18 months (MCPP, p=0.01). At 18 months, healthy children had a 3-fold greater abundance of Bacteroidetes, while children with eczema showed increased abundance of Clostridium clusters IV and XIVa, groups typically abundant in adults rather than infants.
What are the greatest implications of this study?
The findings suggest that eczema in infancy is associated with a microbiota that matures toward an adult-like, Clostridium-dominated profile earlier and with reduced Bacteroidetes compared to healthy at-risk infants. Because the groups looked similar at 6 months but diverged by 18 months, the results point to a developmental window in which microbiota trajectory, not just baseline composition, may matter for eczema risk. This supports using compositional and diversity signatures of the maturing infant microbiota as candidate markers or targets related to atopic eczema.